Despite significant decreases in BCR-ABL mRNA levels in the bone marrow compartment under IM long-term therapy, persistance of residual CML clones with low BCR-ABL expression and insensitivity to IM treatment has been observed [3]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.